Diadema Partners’s Structure Therapeutics GPCR Stock Holding History

Diadema Partners’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-127,500	Closed	-$6.15M	–	168
2026 Q1	$6.15M	Buy	+127,500	New	+$8.73M	1.05%	34

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Diadema Partners's GPCR Position: Q2 2026 in Review

Diadema Partners sold out of Structure Therapeutics (GPCR) in Q2 2026, closing a stake of 72,234 shares — an estimated $3.48M sold.

Diadema Partners first reported a position in GPCR in Q1 2026 and held it in 1 quarter. The position peaked at $3.48M in Q1 2026. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

Diadema Partners reported no remaining Structure Therapeutics position as of Q2 2026 after selling out during the quarter.
Diadema Partners sold 72,234 Structure Therapeutics shares in Q2 2026, an estimated $3.48M.
Diadema Partners first reported a position in Structure Therapeutics in Q1 2026 and held it in 1 quarter.
Diadema Partners's Structure Therapeutics position peaked at $3.48M in Q1 2026.
192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.